Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CNS Pharmaceuticals, Inc. - Common Stock (NQ:CNSP)

1.280 +0.020 (+1.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CNS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q1 Loss, Highlights Progress on TPI 287 for Brain Cancer
Via Investor Brand Network
CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update
Via ACCESS Newswire
Simple Hand Motion Test Could Reveal Undetected Brain Tumor
Via Investor Brand Network
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Prices $5 Million Public Offering with Institutional Investor
Via Investor Brand Network
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
CNS Pharmaceuticals Reports Full Year 2024 Financial Results
Via ACCESS Newswire
CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing
Via ACCESS Newswire
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Orphan Drug Designation Transfer for TPI 287 in Brain Cancer Indications
Via Investor Brand Network
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287
Via ACCESS Newswire
Study Reveals Early Development of Pediatric Brain Tumors in Specialized Nerve Cells
Via Investor Brand Network
AI Can Predict the Recurrence of Brain Tumors in Kids, Study Finds
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Study Identifies Key Enzyme That Could Be Targeted to Fight Brain Cancers
Via Investor Brand Network
CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum
Via ACCESS Newswire
CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
Via ACCESS Newswire
The Global Market for Brain Tumor Treatments Will Reach $7.15 Billion by 2035
Via Investor Brand Network
Study Uncovers Drivers of Brain Tumor Growth, Could Open New Treatment Approaches
Via Investor Brand Network
Pitt Researchers Develop Diagnostic Tool for Profiling Pediatric Brain Cancers
Via Investor Brand Network
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances TPI 287 for GBM, Ends 2024 with Strong Cash Position
Via Investor Brand Network
Firefighters Have an Increased Chance of Having Gene Mutations Associated with Brain Cancer, Study Says
Via Investor Brand Network
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Phase 2 Results for Berubicin in Glioblastoma Trial
Via Investor Brand Network
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme
Via ACCESS Newswire
Study Finds Experimental Drug Prolongs the Survival of Glioblastoma Patients
Via Investor Brand Network
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Updates Cash Position, Nasdaq Compliance, and Clinical Progress
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at European Life Sciences CEO Forum
Via Investor Brand Network
Scientists Discover ‘Roadmap’ Followed by Aggressive Cancers to Spread
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights 2025 Outlook at Virtual Investor Conference
Via Investor Brand Network
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 1-for-50 Reverse Stock Split
Via Investor Brand Network
CNS Pharmaceuticals Announces Reverse Stock Split
Via ACCESS Newswire
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at 6th Glioblastoma Drug Development Summit
Via Investor Brand Network
Exposures Product Safety
CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS